Weight LossMETERMUS-IMCNCT03027479
Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss
A study testing Samples in people with Weight Loss and Ovarian Carcinoma, run by University Hospital, Tours at 1 site in France.
Trial summary
the aim is to study skeletal muscle metabolism alterations métaboliques associated with weight loss in women with ovarian and/or endometrial cancer according to BMI. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Weight Loss, Ovarian Carcinoma, Endometrial Carcinoma
- What is being tested?
- Samples
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteFrance
- Study dates
- 1 Mar 2017to 16 Jul 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women aged 18 years old and more
- Ovarian and/or endometrial cancer
- weight loss related to cancer (weight loss > 5% weight in one month or 10% in 6 months)
- Indication to therapeutic surgery
- Women affiliated to social security scheme
- Women who can understand French and able to sign Informed consent
Show all 10Show fewer
- Women aged 18 years and more
- Surgery Indication for a benign endometrial and/ or ovarian disease
- Patient affiliated to social security scheme
- Women who can understand French and able to sign Informed consent
Who cannot join
- Unbalanced Diabetes
- Chronic neuromuscular disorder
- Any severe uncontrolled medical condition
- Control group selection criteria:
- Unbalanced Diabetes
- Chronic neuromuscular disorder
- Any severe uncontrolled medical condition
Trial locations and contacts
1 site in 1 country.
France1 site
Gynecology Department, University Teaching Hospital, Tours
Tours, 37044
About this study
Official title: Study of Differences in Skeletal Muscle Energy Metabolism Alterations in Women With Weight Loss and Ovarian and/or Endometrial Cancer Based on the Body Mass Index
the aim is to study skeletal muscle metabolism alterations métaboliques associated with weight loss in women with ovarian and/or endometrial cancer according to BMI.
- Conditions
- Weight Loss, Ovarian Carcinoma, Endometrial Carcinoma
- Being tested
- Samples
- Keywords
- weight loss, ovarian cancer, endometrial cancer, energy metabolism, Body mass index, obesity, muscle energy
- Medical subject headings
- Weight Loss, Ovarian Neoplasms, Endometrial Neoplasms, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SamplesOther
Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
| Study group | Role | What they receive |
|---|---|---|
| Case group | Experimental | women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples Receives: Other: Samples |
| Control group | Other | women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples Receives: Other: Samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of muscle mitochondrial bioenergetics according to BMI
Measurement of muscle mitochondrial bioenergetics by high resolution oxygraphy
Measured: muscle biopsy realized during surgery
Secondary outcomes (4)
on muscle biopsy
- Quantification of lipids on electron microscope
- Type of muscular fibers
- Analyze of gene expression and proteins involved in 1/ Mitochondrial metabolism 2/ lipid metabolism and 3/ muscular proteolysis by RTqPCR with SyBR Green and Western Blot
Measured: muscle biopsy realized during surgery
on white adipose tissue
adipose tissue composition (fatty acids quantification, sterols, steroids)
- RT-qPCR quantification of molecules involved in lipid metabolism (synthesis, transport) and in inflammation (immune profile and cytokines)
- RTqPCR analysis, western blot and immunohistochemical expression of markers of transformation into brown adipose tissue
- in specific milieu, in vitro experimentation on skeletal muscular cells
Measured: adipose tissue samples taken during surgery
on ovarian cancer tumor samples
- lipid composition (fatty acids quantification, sterols, steroids)
- RT-qPCR quantification of molecules involved in lipid metabolism (synthesis, transport) and in inflammation (immune profil and cytokines)
- culture of tumour cells to evaluate resistance to chemotherapy (platinum)
Measured: ovarian tumor biopsies realized during surgery
on computerized tomography
assessment of body composition (fat and muscle compartments)
Measured: 1 day of abdominal CT scan imaging procedure performed at diagnosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2017 (estimated)
- Study start1 Mar 2017
- Primary completion16 Jul 2019
- Study completion16 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Weight LossStudies of the same condition, open and under way.
- More trials run by University Hospital, ToursThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Tours
- Sponsor type
- University, hospital or other
- Collaborators
- Inserm U1069 - Team Nutrition, Growth and Cancer
- Responsible party
- Sponsor
- Investigators
- Lobna OULDAMER, MD, PhD, Principal investigator, University Teaching Hospital of Tours
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03027479
- Sponsor's protocol ID
- PHAO16-LO/METERMUS-IMC
- Other IDs
- 2016-A01323-48, 2016-R27
- Acronym
- METERMUS-IMC
- Status last verified
- Dec 2025
- First submitted
- 19 Jan 2017
- Last updated
- 22 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Salaun H, Poisson M, Dolly A, Arbion F, Servais S, Dumas JF, Goupille C, Ouldamer L. Total Polyunsaturated Fatty Acid Level in Abdominal Adipose Tissue as an Independent Predictor of Recurrence-Free Survival in Women with Ovarian Cancer. Int J Mol Sci. 2023 Jan 16;24(2):1768. doi: 10.3390/ijms24021768.
PubMed 36675280
Study at a glance
From the registry record, last updated by the sponsor on 22 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Differences in Skeletal Muscle Energy Metabolism Alterations in Women With Weight Loss and Ovarian and/or Endometrial Cancer Based on the Body Mass Index
- ClinicalTrials.gov ID
- NCT03027479
- Acronym / sponsor ID
- METERMUS-IMC / PHAO16-LO/METERMUS-IMC
- Conditions
- Weight Loss, Ovarian Carcinoma, Endometrial Carcinoma
- Keywords
- weight loss, ovarian cancer, endometrial cancer, energy metabolism, Body mass index, obesity, muscle energy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- University Hospital, ToursUniversity, hospital or other
- Collaborators
- Inserm U1069 - Team Nutrition, Growth and Cancer
- Study start
- 1 Mar 2017 (actual)
- Primary completion
- 16 Jul 2019 (actual)
- Study completion
- 16 Jul 2019 (actual)
- First posted
- 23 Jan 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the aim is to study skeletal muscle metabolism alterations métaboliques associated with weight loss in women with ovarian and/or endometrial cancer according to BMI.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Case group | Experimental | Other: Sampleswomen with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples |
| Control group | Other | Other: Sampleswomen scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Women aged 18 years old and more
- Ovarian and/or endometrial cancer
- weight loss related to cancer (weight loss > 5% weight in one month or 10% in 6 months)
- Indication to therapeutic surgery
- Women affiliated to social security scheme
Key exclusion criteria (7 listed)
- Unbalanced Diabetes
- Chronic neuromuscular disorder
- Any severe uncontrolled medical condition
- Unbalanced Diabetes
- Chronic neuromuscular disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SamplesBlood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample | Other | Case group, Control group |
Primary outcome
Measurement of muscle mitochondrial bioenergetics according to BMI
Time frame: muscle biopsy realized during surgery
Measurement of muscle mitochondrial bioenergetics by high resolution oxygraphy
4 secondary outcomes
on muscle biopsy
Time frame: muscle biopsy realized during surgery
on white adipose tissue
Time frame: adipose tissue samples taken during surgery
on ovarian cancer tumor samples
Time frame: ovarian tumor biopsies realized during surgery
on computerized tomography
Time frame: 1 day of abdominal CT scan imaging procedure performed at diagnosis
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Dec 2025.
- Results publication: PubMed 36675280Salaun H, Poisson M, Dolly A, Arbion F, Servais S, Dumas JF, Goupille C, Ouldamer L. Total Polyunsaturated Fatty Acid Level in Abdominal Adipose Tissue as an Independent Predictor of Recurrence-Free Survival in Women with Ovarian Cancer. Int J Mol Sci. 2023 Jan 16;24(2):1768. doi: 10.3390/ijms24021768.
- Individual participant dataSharing planned: No
Related trials for Weight Loss
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
A Pilot Factorial Trial of an Integrated Lifestyle Intervention
Physical Inactivity, Overweight and Obesity
RecruitingPhase 1/2
Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia
Cancer, Cachexia
Active, not recruitingPhase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Diabetes Mellitus, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lobna OULDAMER, MD, PhD principal investigator
University Teaching Hospital of Tours
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Samples in people with Weight Loss and Ovarian Carcinoma, run by University Hospital, Tours at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of muscle mitochondrial bioenergetics according to BMI (time frame: muscle biopsy realized during surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03027479, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2025.